ABBOTT-CITALOPRAM TABLET

Quốc gia: Canada

Ngôn ngữ: Tiếng Anh

Nguồn: Health Canada

Thành phần hoạt chất:

CITALOPRAM (CITALOPRAM HYDROBROMIDE)

Sẵn có từ:

ABBOTT LABORATORIES, LIMITED

Mã ATC:

N06AB04

INN (Tên quốc tế):

CITALOPRAM

Liều dùng:

20MG

Dạng dược phẩm:

TABLET

Thành phần:

CITALOPRAM (CITALOPRAM HYDROBROMIDE) 20MG

Tuyến hành chính:

ORAL

Các đơn vị trong gói:

100/500

Loại thuốc theo toa:

Prescription

Khu trị liệu:

SELECTIVE-SEROTONIN REUPTAKE INHIBITORS

Tóm tắt sản phẩm:

Active ingredient group (AIG) number: 0136243001; AHFS:

Tình trạng ủy quyền:

CANCELLED POST MARKET

Ngày ủy quyền:

2015-12-31

Đặc tính sản phẩm

_ _
_Abbott-Citalopram Product Monograph _
_Page 1 of 48_
PRODUCT MONOGRAPH
PR
ABBOTT-CITALOPRAM _ _
Citalopram Tablets USP
10 mg, 20 mg and 40 mg citalopram (as citalopram hydrobromide)
Antidepressant
BGP Pharma Inc.
8401 Trans-Canada Highway
Saint-Laurent, Quebec
H4S 1Z1
Date of Preparation:
January 7, 2015
Submission Control No.: 180716
_ _
_Abbott-Citalopram Product Monograph _
_Page 2 of 48 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
..................................................................................................12
DRUG INTERACTIONS
..................................................................................................19
DOSAGE AND ADMINISTRATION
..............................................................................25
OVERDOSAGE
................................................................................................................27
ACTION AND CLINICAL PHARMACOLOGY
............................................................28
STORAGE AND STABILITY
..........................................................................................29
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................30
PART II: SCIENTIFIC INFORMATION
...............................................................................31
PHARMACEUTICAL INFORMATION
..........................................................................31
CLINICAL TRIALS
.......................................................................................